| A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis (NCT07684157) | Jacobio Pharmaceuticals Co., Ltd. | 2026-07-29 |
| Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations (NCT07640295) | Jacobio Pharmaceuticals Co., Ltd. | 2026-06-22 |
| A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration (NCT06959615) | Jacobio Pharmaceuticals Co., Ltd. | 2024-11-22 |
| JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation (NCT06386146) | Jacobio Pharmaceuticals Co., Ltd. | 2024-07-24 |
| JAB-2485 Activity in Adult Patients With Advanced Solid Tumors (NCT05490472) | Jacobio Pharmaceuticals Co., Ltd. | 2022-12-20 |
| JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors (NCT05174585) | Jacobio Pharmaceuticals Co., Ltd. | 2022-08-18 |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors (NCT04686682) | Jacobio Pharmaceuticals Co., Ltd. | 2021-05-07 |
| JAB-3068 Activity in Adult Patients With Advanced Solid Tumors (NCT04721223) | Jacobio Pharmaceuticals Co., Ltd. | 2021-04-26 |
| A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors (NCT04587479) | Jacobio Pharmaceuticals Co., Ltd. | 2020-11-23 |
| A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors (NCT04045496) | Jacobio Pharmaceuticals Co., Ltd. | 2019-09-26 |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China (NCT03565003) | Jacobio Pharmaceuticals Co., Ltd. | 2018-11-20 |
| A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors (NCT03518554) | Jacobio Pharmaceuticals Co., Ltd. | 2018-04-23 |